FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

Vitamin D deficiency is strongly associated with an increased risk of severe acute exacerbations in patients with chronic ...

Acute Care Interventions in Patients Hospitalized Due to COPD Exacerbation Before and After Implementation of an Integrated ...

During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...

A new study published in JAMA Network Open has found that while procedural prescription denials curb immediate drug costs, some denials result in increased acute care utilization and costs, which ...

Acute renal failure is caused by damage to the kidneys, which can occur as a result of blood loss, toxins, or physical damage to the kidneys. Acute renal failure occurs rapidly, causing generalized ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published.

Your healthcare team can best advise you on treatment for COPD exacerbations. If you live with chronic obstructive pulmonary disease (COPD), you may experience shortness of breath, wheezing ...

The annualized rate of moderate or severe COPD exacerbations at 52 weeks was 1.75 for tezepelumab compared with 2.11 for placebo. Tezepelumab did not significantly decrease the annualized rate of ...